ATE73856T1 - Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren. - Google Patents

Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.

Info

Publication number
ATE73856T1
ATE73856T1 AT86900138T AT86900138T ATE73856T1 AT E73856 T1 ATE73856 T1 AT E73856T1 AT 86900138 T AT86900138 T AT 86900138T AT 86900138 T AT86900138 T AT 86900138T AT E73856 T1 ATE73856 T1 AT E73856T1
Authority
AT
Austria
Prior art keywords
tnf
purification
preparation
tumor necrosis
necrosis factors
Prior art date
Application number
AT86900138T
Other languages
English (en)
Inventor
Walter C Fiers
Lucia M Fransen
Jan Honore Leo Tavernier
Anne Louis Marie Marmenout
Der Heyden Jose Van
Bernard Allet
Eric H Kawashima
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE73856T1 publication Critical patent/ATE73856T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT86900138T 1984-12-21 1985-12-19 Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren. ATE73856T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68459584A 1984-12-21 1984-12-21
US78584785A 1985-10-09 1985-10-09
PCT/EP1985/000721 WO1986003751A2 (en) 1984-12-21 1985-12-19 Purification, production and use of tumor necrosis factors
EP86900138A EP0216786B1 (de) 1984-12-21 1985-12-19 Reinigung, herstellung und verwendung von tumor-nekrosisfaktoren

Publications (1)

Publication Number Publication Date
ATE73856T1 true ATE73856T1 (de) 1992-04-15

Family

ID=27103367

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86900138T ATE73856T1 (de) 1984-12-21 1985-12-19 Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.

Country Status (16)

Country Link
US (1) US5487984A (de)
EP (3) EP0216786B1 (de)
JP (4) JP2557053B2 (de)
KR (1) KR940010865B1 (de)
AT (1) ATE73856T1 (de)
AU (2) AU601675B2 (de)
DE (1) DE3585690D1 (de)
DK (1) DK399786D0 (de)
ES (1) ES8705521A1 (de)
FI (1) FI86194C (de)
HU (1) HUT40702A (de)
IE (1) IE58709B1 (de)
NO (1) NO855216L (de)
NZ (1) NZ214711A (de)
PT (1) PT81754B (de)
WO (1) WO1986003751A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
CA1340998C (en) * 1986-02-04 2000-05-23 Den'ichi Mizuno Dnas and processes for their preparation, novel plasmids possessing them, novel polypeptides and processes for their preparation and novel anti-tumor agents comprising said polypeptides
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
WO1991006658A2 (en) * 1989-10-24 1991-05-16 Cetus Corporation Infective protein delivery system
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JP2930723B2 (ja) * 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
US5715835A (en) * 1992-11-19 1998-02-10 Anticancer, Inc. Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
US6461851B1 (en) 1992-11-19 2002-10-08 Anticancer, Inc. High expression modules containing two or more tandem copies of a methioninase encoding sequence
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
WO1996012730A1 (en) * 1994-10-20 1996-05-02 Industrial Research Limited Separation of amino acids and peptides from protein hydrolysates
PT897390E (pt) * 1996-03-14 2004-03-31 Human Genome Sciences Inc Factor delta e epsilon de necrose tumoral humana
AU2003236393B2 (en) * 1996-03-14 2006-02-02 Human Genome Sciences, Inc. Methods of Treating or Preventing Inflammation or Rheumatoid Arthritis
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
AU761216B2 (en) * 1996-03-14 2003-05-29 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7217788B2 (en) * 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6509170B1 (en) 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
EP1401870A4 (de) * 2001-05-24 2006-04-19 Human Genome Sciences Antikörper gegen tumor necrosis factor delta (april)
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
JP2005132795A (ja) * 2003-10-31 2005-05-26 Genichiro Soma 抗悪性神経膠腫剤及び動物用抗悪性神経膠腫剤
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
PT2953634T (pt) 2013-02-07 2021-09-02 Massachusetts Gen Hospital Métodos de expansão ou depleção das células t reguladoras
CN111239415B (zh) 2013-10-17 2024-03-26 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
JP2017525370A (ja) * 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (de) 2015-08-28 2019-06-12 The General Hospital Corporation Agonistische anti-tumor-nekrosefaktorrezeptor-2-antikörper
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
EP3455262A4 (de) 2016-05-13 2020-04-08 The General Hospital Corporation Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
NL7903195A (nl) 1979-04-24 1980-10-28 Philips Nv Inrichting voor kunstmatige nagalm.
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE63126B1 (en) 1980-06-06 1995-03-22 Biogen Inc Improved vectors and methods for making such vectors and for expressing cloned genes
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
AU8956582A (en) * 1982-10-06 1984-04-24 Makitsubo, T. Process for extracting tumor necrosis factor from macrophage
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
DE3472793D1 (en) * 1983-12-26 1988-08-25 Asahi Chemical Ind A novel physiologically active polypeptide
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (de) * 1984-07-05 1985-11-26 Genentech Inc
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4677663A (en) * 1985-07-05 1987-06-30 Melita Electronic Labs, Inc. Telephone answering and call forwarding improvement
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5182196A (en) * 1985-10-09 1993-01-26 Biogen, Inc. Expression systems for overproduction of desired proteins

Also Published As

Publication number Publication date
JP2557053B2 (ja) 1996-11-27
JP2548527B2 (ja) 1996-10-30
AU601675B2 (en) 1990-09-20
FI855130A0 (fi) 1985-12-20
WO1986003751A3 (en) 1986-08-14
PT81754B (pt) 1987-12-30
DK399786A (da) 1986-08-21
AU5301486A (en) 1986-07-22
FI855130A7 (fi) 1986-06-22
AU5510490A (en) 1990-10-25
IE853273L (en) 1986-06-21
PT81754A (en) 1986-01-02
IE58709B1 (en) 1993-11-03
ES8705521A1 (es) 1987-05-01
EP0313104A3 (de) 1989-07-12
JPH07213292A (ja) 1995-08-15
NO855216L (no) 1986-06-23
ES550260A0 (es) 1987-05-01
JP2548525B2 (ja) 1996-10-30
KR860005023A (ko) 1986-07-16
WO1986003751A2 (en) 1986-07-03
JP2548526B2 (ja) 1996-10-30
EP0216786B1 (de) 1992-03-18
DE3585690D1 (de) 1992-04-23
JPS62501470A (ja) 1987-06-18
FI86194B (fi) 1992-04-15
JPH07213293A (ja) 1995-08-15
FI86194C (fi) 1992-07-27
EP0368367A1 (de) 1990-05-16
JPH07213291A (ja) 1995-08-15
KR940010865B1 (ko) 1994-11-18
DK399786D0 (da) 1986-08-21
HUT40702A (en) 1987-01-28
EP0216786A1 (de) 1987-04-08
EP0313104A2 (de) 1989-04-26
NZ214711A (en) 1991-11-26
US5487984A (en) 1996-01-30

Similar Documents

Publication Publication Date Title
ATE73856T1 (de) Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
FR2564859B1 (fr) Procede de preparation d'acide hyaluronique par fermentation.
EP0179390A3 (de) L-Lysin- und L-Histidinpyruvat
ES544587A0 (es) Procedimiento para la microfiltracion en flujo cruzado de vino
FI902017A0 (fi) Foerfarande foer rengoering av protein.
DK138085D0 (da) Fremgangsmaade til fremstilling af l-carnitin paa mikrobiologisk maade
ATE80520T1 (de) Photodynamische unkrautvertilger.
FI102039B1 (fi) Menetelmä aktiivisen yhdistelmä-DNA-humaani-interleukiini-4:n raakaliuoksen puhdistamiseksi
DE69411492D1 (de) Verfahren zur Reinigung von mittleren Olefinen
DE3583245D1 (de) Herstellung von aminosaeuren durch biologischen austausch.
FR2552424B1 (fr) Procede de preparation de 1,1,1,3,3,3-hexafluoropropane-2-ol par hydrogenolyse de l'hydrate d'hexafluoroacetone
DE3580007D1 (de) Verfahren zur reinigung von rohem beta-phenylethylalkohol.
DK380785A (da) S-6-fluor-4-aminochroman-4-carboxylsyre-forbindelser og salte deraf, fremgangsmaade til fremstilling deraf og anvendelse deraf til fremstilling af sorbinil
KR960023063A (ko) 재조합 인간 과립구 대식세포 콜로니 자극인자의 개선된 정제방법
FR2633612B1 (fr) Procede de purification de dihydroxybiphenyles
DE3668887D1 (de) Verfahren zur reinigung von 3,3'-dinitrodiphenyl-verbindungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee